Hormone Receptor-positive Breast Cancer Clinical Trial
Official title:
A Phase I Trial of Capecitabine in Combination With Cemiplimab in Patients With Hormone Receptor Positive Metastatic Breast Cancer
This is a single-center, open-label, phase I study to assess the safety and efficacy of the oral chemotherapy capecitabine in combination with cemiplimab in patients with hormone-receptor-positive (HR+) metastatic breast cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05766410 -
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
|
Phase 2 | |
| Recruiting |
NCT05467891 -
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04997941 -
Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT05452213 -
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
|
Phase 4 | |
| Recruiting |
NCT05501704 -
ETHAN - ET for Male BC
|
Phase 2 | |
| Not yet recruiting |
NCT05122377 -
RWE About QOL and Compliance of Patients With OFS in China
|
||
| Not yet recruiting |
NCT04891731 -
Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer
|
||
| Terminated |
NCT04942054 -
A Study in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04706962 -
TH1902 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Suspended |
NCT05503108 -
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT04925284 -
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
|
Phase 1 | |
| Withdrawn |
NCT04602117 -
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT01177397 -
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05165225 -
Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial
|
Phase 2 | |
| Recruiting |
NCT05573126 -
Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05608252 -
VS-6766+Abema+Fulv in Met HR+/HER- BC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05868226 -
PRE-I-SPY Phase I/Ib Oncology Platform Program
|
Phase 1 | |
| Recruiting |
NCT05115474 -
Study of Screening Brain MRIs in Stage IV Breast Cancer
|
||
| Not yet recruiting |
NCT05651087 -
Evaluate Efficacy and Safety of LACUDY for Improving Vaginal Environment in Breast Cancer Patient
|
N/A | |
| Recruiting |
NCT05524584 -
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
|
Phase 2 |